The deal includes Caplyta, a treatment for schizophrenia and bipolar depression, along with a pipeline focused on disorders such as generalized anxiety and Alzheimer’s-related psychosis, according to an Jan. 13 news release from the company.
The acquisition bolsters J&J’s neuroscience portfolio, with Caplyta expected to generate more than $5 billion in peak annual sales. It also strengthens the company’s position in central nervous system therapies, including ongoing Phase 3 trials for bipolar mania and schizophrenia relapse prevention, the release said.
The deal is expected to close later in 2025, pending regulatory approval.
